Table 1. Characteristics of studies included in the meta-analysis.
| Authors (year) | Design | Population | Dose of sorafenib | Treatment duration | Follow-up time(range) | Outcomes | References |
|---|---|---|---|---|---|---|---|
| Wei Zhang (2014) |
Retrospective with historical control | Patients with HCC after curative resection | 400 mg twice daily | One month | – | Overall survival; recurrence rate and mortality rate | 12 |
| Shen-Nien Wang (2014) | Open-label, controlled phase II trail | Patients with HCC after curative resection | 400 mg q.d | 4 months | 9.5-30.2 months | Recurrence rate; mortality rate | 13 |
| Lei Zhuang (2014) | Retrospective with historical control | Patients with HCC after curative resection | 400 mg twice daily | – | 13–44 months | Overall survival; mortality rate | 14 |
| Jiang Li (2016) | Retrospective with historical control | BCLC stage C HCC after curative resection | 200–800 mg/d | One month | 9–54 months | Overall survival; recurrence rate; mortality rate | 15 |
| Bingfeng Chen (2016) | Prospective controlled trail | Patients with HCC after curative resection | 400 mg twice daily | 6 months | 36–60 months | Overall survival; recurrence rate; mortality rate | 16 |
HCC: Hepatocellular carcinoma